These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9137693)

  • 1. Interview with Jean-Pierre Revillard. What is going to happen tomorrow as far as treatment of autoimmune disorders is concerned?
    Revillard JP
    Ann Med Interne (Paris); 1997; 148(1):11-4. PubMed ID: 9137693
    [No Abstract]   [Full Text] [Related]  

  • 2. Interview with Peter Lydyard. What is going to happen tomorrow as far as heat-shock proteins are concerned?
    Lydyard P
    Ann Med Interne (Paris); 1993; 144(2):97-8. PubMed ID: 8333667
    [No Abstract]   [Full Text] [Related]  

  • 3. [An interview with Sylviane Muller by P Youinou. What is going to happen tomorrow in the field of synthetic peptides of autoantigens?].
    Muller S
    Ann Med Interne (Paris); 1993; 144(5):319-22. PubMed ID: 8291840
    [No Abstract]   [Full Text] [Related]  

  • 4. [Trends in the treatment of immunologic system diseases].
    Tonietti G; Passacantando A
    Recenti Prog Med; 1999 Nov; 90(11):575-8. PubMed ID: 10608145
    [No Abstract]   [Full Text] [Related]  

  • 5. [Interview with Jean-François Borel. What is going to happen tomorrow in the field of cyclosporine?].
    Borel JF
    Ann Med Interne (Paris); 1995; 146(4):251-3. PubMed ID: 7653946
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunosuppressive therapy of autoimmune diseases.
    Bach JF
    Trends Pharmacol Sci; 1993 May; 14(5):213-6. PubMed ID: 8212318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coincident membranous glomerulonephritis and chronic inflammatory demyelinating polyradiculoneuropathy: questioning the autoimmunity hypothesis.
    Smyth S; Menkes DL
    Muscle Nerve; 2008 Jan; 37(1):130-5. PubMed ID: 17614320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentostatin (Nipent) and high-dose cyclophosphamide for the treatment of refractory autoimmune disorders.
    Goodman M
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):67-71. PubMed ID: 10877056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interview with Joachim Robert Kalden. What is going to happen tomorrow as far as DNA and anti-DNA antibodies are concerned?. Interview by P. Youinou.
    Kalden JR
    Ann Med Interne (Paris); 1993; 144(7):463-4. PubMed ID: 8141512
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of pemphigus with methotrexate].
    Jablońska S; Blaszczyk M
    Przegl Dermatol; 1970; 57(3):331-6. PubMed ID: 5433513
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunomodulation therapy for autoimmune diseases. New hope for patients with autoimmune diseases].
    Szegedi G
    Orv Hetil; 2005 Apr; 146(14):635-43. PubMed ID: 15889537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in autoimmune pancytopenia: a case report and review of literature.
    Reale LD; Besa EC
    Ann Hematol; 2007 Dec; 86(12):913-6. PubMed ID: 17541587
    [No Abstract]   [Full Text] [Related]  

  • 13. [Interview with Pierre Godeau, President of the Société Nationale Française de Médecine Interne. What is going to happen tomorrow in internal medicine?. Interview by Pierre Youinou].
    Godeau P
    Ann Med Interne (Paris); 1994; 145(1):3-6. PubMed ID: 8192278
    [No Abstract]   [Full Text] [Related]  

  • 14. Interview with Ivan M. Roitt. What is going to happen tomorrow as far as glycosylation of IgG is concerned?. Interview by P. Youinou.
    Roitt IM
    Ann Med Interne (Paris); 1993; 144(6):389-91. PubMed ID: 8122821
    [No Abstract]   [Full Text] [Related]  

  • 15. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunointervention in newly diagnosed type 1 diabetes].
    Kaupper T; Walter M; Ziegler AG
    Dtsch Med Wochenschr; 2006 Dec; 131(49):2783-8. PubMed ID: 17136660
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of autoimmune diseases].
    Tomer Y; Ben-Yehuda O; Shoenfeld Y
    Harefuah; 1987 Jun; 112(12):608-12. PubMed ID: 3322969
    [No Abstract]   [Full Text] [Related]  

  • 18. Risks of combining immunosuppressive and biological treatments in inflammatory bowel disease.
    Roblin X; Phelip JM
    Arch Intern Med; 2008 Mar; 168(6):667; author reply 667-8. PubMed ID: 18362263
    [No Abstract]   [Full Text] [Related]  

  • 19. Interview with Frank Hay. What is going to happen tomorrow as far as rheumatoid factor is concerned?
    Hay F
    Ann Med Interne (Paris); 1995; 146(7):479-80. PubMed ID: 8787288
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduction of acquired high titer factor VIII antibodies by extracorporeal antibody-based immunoadsorption without additional immunosuppressive therapy.
    Toepfer M; Rommel F; Sitter T; Spannagl M; Held E; Schramm W; Schiffl H
    Thromb Haemost; 1998 Dec; 80(6):1035-6. PubMed ID: 9869185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.